Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma.

Interestingly, while IL-6 levels were elevated in the quadruple DT/α-PD-1/α-OX40 treated mice, the magnitude was lower than in the triplet DT/α-OX40 treated mice and did not reach statistical significance (222 pg/ml; p = .44) (Supplementary Figure S5).

also in 111,027 other papers